TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07059000: A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)

Sponsor: Kedrion S.p.A. · Phase: PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 40 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,772,230

Rescue Site Savings

+$2,498,490

Unlock Full NCT07059000 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07059000 Rescue Dossier →